Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Triple Negative Breast Neoplasms

Head and Neck Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Irinotecan

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Topoisomerase I Inhibitors

Enzyme Inhibitors

Immunologic Factors

MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks

MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks

MM-151

MM-151 + irinotecan

This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.

This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design exploring weekly, bi-weekly, and tri-weekly dosing schedules. Successive MM-151 monotherapy cohorts of three or more patients will be treated at escalating doses until a maximum tolerated dose is identified, and subsequently in combination with irinotecan. The study consists of three parts as follows: MM-151 monotherapy dose escalation (Part 1); MM-151 monotherapy expansion cohort in cetuximab-refractory colorectal cancer (Part 2); MM-151 + irinotecan dose escalation (Part 3). It is expected that approximately 4 study sites will participate.

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors

Merrimack Pharmaceuticals

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment	NCT01520389	Advanced Solid ... Colorectal Canc... Squamous Cell H... Non Small Cell ... Triple Negative...	MM-151 MM-151 + irinot...	18 Years -	Merrimack Pharmaceuticals
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment	NCT01520389	Advanced Solid ... Colorectal Canc... Squamous Cell H... Non Small Cell ... Triple Negative...	MM-151 MM-151 + irinot...	18 Years -	Merrimack Pharmaceuticals

Spots Global Cancer Trial Database for egf receptor (erbb1)